Amylin reportedly stiff-armed $3.5B offer from BMS

Amylin Pharmaceuticals ($AMLN) reportedly shot down a $22-per-share offer from Bristol-Myers Squibb ($BMY), a deal that could have been worth $3.5 billion--and added another pearl to BMS's growing strand. It's unclear why Amylin rejected the Big Pharma proposal, but in any case, BMS hasn't come back for another try. Report